Can I Take Methotrexate With an MTHFR Gene Variant?
At a Glance
Common MTHFR variants such as C677T and A1298C do not usually mean you must avoid methotrexate or change the dose. Your doctor should base safety decisions on kidney and liver function, other medicines, weekly dosing, and routine blood tests.
No, having a common MTHFR gene variant (often referred to as a mutation) does not mean you must avoid taking methotrexate. While some genetic variants may be associated with a slightly higher chance of side effects in studies, they do not reliably predict how your individual body will react. Major pharmacogenomic guidelines—including those from the Clinical Pharmacogenetics Implementation Consortium (CPIC) and the Dutch Pharmacogenetics Working Group (DPWG) (organizations that guide how genetics affect drug responses)—do not consider common MTHFR variants to be a reason to avoid the drug or to automatically change your dose [1][2].
If a genetic test (such as 23andMe or a report from a healthcare provider) shows you have the C677T or A1298C variants, it is important to understand that these are very common in the general population. They are not the same as a rare, severe MTHFR deficiency disease, and they do not mean your body is unable to process ordinary folic acid [3]. Your doctor will base your treatment on your kidney function, liver function, other medications, and overall health—clinical factors that matter far more for your safety than your MTHFR genetic status.
Safe Dosing and Crucial Warning Signs
When prescribed for inflammatory conditions like rheumatoid arthritis, methotrexate is taken exactly once weekly—not daily. Taking it daily by mistake can cause life-threatening toxicity. Never double your dose if you miss one, and contact your doctor immediately if you accidentally take an extra dose.
When to Seek Medical Help:
While taking methotrexate, you must actively watch for signs of toxicity. Do not wait for your next appointment. Contact your prescriber urgently or seek emergency care if you develop:
- Severe or persistent mouth sores (ulcers)
- Fever, chills, or sore throat (signs of an infection)
- Unusual bruising or bleeding
- Severe or persistent vomiting or diarrhea
- Yellowing of your skin or eyes (jaundice) or dark urine (signs of liver damage)
- A severe skin rash or blistering
- A new, dry cough or unusual shortness of breath
What is the MTHFR Gene?
The MTHFR gene provides instructions for making an enzyme that helps your body process folate (vitamin B9) into an active form that your cells can use [3]. Methotrexate works by interfering with how your body uses folate, which helps suppress an overactive immune system.
The two most common variants are C677T and A1298C. Inheriting one or two copies of these variants can slightly reduce the activity of the MTHFR enzyme [3][4].
Does the Variant Increase Toxicity Risk?
The relationship between MTHFR variants and methotrexate side effects is mixed and depends on the specific variant:
| Variant | What the Evidence Shows | Recommended Action |
|---|---|---|
| C677T | Some studies show an association with increased side effects, such as elevated liver enzymes (a sign of liver inflammation in the blood), especially in people with two copies (the TT genotype) [5][6]. However, results vary widely across different populations and studies [7]. | Continue standard protocol-based blood monitoring. Genotype alone does not justify a dose change [1]. |
| A1298C | Research shows no consistent overall association with methotrexate toxicity or treatment effectiveness [8][9]. | Continue standard protocol-based blood monitoring. No action needed based on genotype [1]. |
It is crucial to note that many studies reporting high toxicity risks evaluated the massive doses of methotrexate used in cancer treatments. Those risks cannot be directly applied to the much lower weekly doses used in rheumatology [10][11].
Folic Acid and Routine Monitoring
Because methotrexate depletes folate, your doctor will routinely prescribe a folic acid supplement to help prevent side effects like mouth sores and nausea [12]. While folic acid helps reduce these risks, it does not make methotrexate entirely risk-free.
- Follow your exact schedule: Folic acid is usually taken daily or on specific days of the week, depending on your doctor’s protocol. Follow your exact prescription. Do not increase your dose, switch to a different supplement like methylfolate, or substitute it with folinic acid (a stronger prescription rescue medicine) just because of a genetic report [1][13].
- Routine blood tests: Regular laboratory testing is the safest and most reliable way to monitor for unseen toxicity. Before and during treatment, your doctor will check a complete blood count (CBC), liver tests, and kidney function [14].
- Baseline folate levels: Your doctor may test your actual folate and vitamin B12 levels in your blood if they suspect a deficiency based on your medical history or diet. Testing is not automatically required for everyone with an MTHFR variant.
Common questions in this guide
Is it safe to take methotrexate if I have an MTHFR variant?
Does C677T or A1298C make methotrexate toxicity more likely?
Should my methotrexate dose be changed because of an MTHFR test?
How should I take methotrexate for an inflammatory condition?
Why am I prescribed folic acid with methotrexate?
What monitoring is needed while taking methotrexate?
Which symptoms could signal methotrexate toxicity?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Given my overall health and other medications, are there specific side effects I should monitor more closely while taking methotrexate?
- 2.What early warning signs of methotrexate toxicity should prompt me to contact you between my scheduled appointments?
- 3.What is the exact schedule I should follow for taking my weekly methotrexate and my folic acid supplement?
- 4.How frequently will we be doing routine blood tests to check my liver, kidney, and blood counts?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (14)
- 1
Dutch pharmacogenetics working group guideline for the gene-drug interaction of ABCG2, HLA-B and Allopurinol, and MTHFR, folic acid and methotrexate.
van der Pol KH, Nijenhuis M, Soree B, et al.
European journal of human genetics : EJHG 2024; (32(2)):155-162 doi:10.1038/s41431-022-01180-0.
PMID: 36056234 - 2
The impact of gene polymorphisms on the response of methotrexate-based treatments.
Esperón P, Vital M, Giletti A
European journal of clinical pharmacology 2026; (82(6)).
PMID: 42104114 - 3
MTHFR C677T and A1298C Polymorphisms in Breast Cancer, Gliomas and Gastric Cancer: A Review.
Petrone I, Bernardo PS, Dos Santos EC, Abdelhay E
Genes 2021; (12(4)) doi:10.3390/genes12040587.
PMID: 33920562 - 4
More severe toxicity of genetic polymorphisms on MTHFR activity in osteosarcoma patients treated with high-dose methotrexate.
Xie L, Guo W, Yang Y, et al.
Oncotarget 2018; (9(14)):11465-11476 doi:10.18632/oncotarget.23222.
PMID: 29545912 - 5
Association Between MTHFR C677T Polymorphism and Methotrexate Treatment Outcome in Rheumatoid Arthritis Patients: A Systematic Review and Meta-Analysis.
Shao W, Yuan Y, Li Y
Genetic testing and molecular biomarkers 2017; (21(5)):275-285 doi:10.1089/gtmb.2016.0326.
PMID: 28277784 - 6
Associations between single-nucleotide polymorphisms of RFC-1, GGH, MTHFR , TYMS, and TCII genes and the efficacy and toxicity of methotrexate treatment in patients with rheumatoid arthritis.
Świerkot J, Ślęzak R, Karpiński P, et al.
Polskie Archiwum Medycyny Wewnetrznej 2015; (125(3)):152-61.
PMID: 25599563 - 7
Mutations in the MTHFR gene are not associated with Methotrexate intolerance in patients with juvenile idiopathic arthritis.
Scheuern A, Fischer N, McDonald J, et al.
Pediatric rheumatology online journal 2016; (14(1)):11 doi:10.1186/s12969-016-0071-y.
PMID: 26928923 - 8
Lack of association between MTHFR A1298C polymorphism and outcome of methotrexate treatment in rheumatoid arthritis patients: evidence from a systematic review and meta-analysis.
Fan H, Li Y, Zhang L, et al.
International journal of rheumatic diseases 2017; (20(5)):526-540 doi:10.1111/1756-185X.13100.
PMID: 28544525 - 9
MTHFR, TYMS and SLCO1B1 polymorphisms and adverse liver effects of methotrexate in rheumatoid arthritis.
Sundbaum JK, Baecklund E, Eriksson N, et al.
Pharmacogenomics 2020; (21(5)):337-346 doi:10.2217/pgs-2019-0186.
PMID: 32024416 - 10
The Role of Genetic Polymorphisms in High-Dose Methotrexate Toxicity and Response in Hematological Malignancies: A Systematic Review and Meta-Analysis.
Song Z, Hu Y, Liu S, et al.
Frontiers in pharmacology 2021; (12()):757464 doi:10.3389/fphar.2021.757464.
PMID: 34744734 - 11
MTHFR gene polymorphisms and methotrexate toxicity in adult patients with hematological malignancies: a meta-analysis.
Zhao M, Liang L, Ji L, et al.
Pharmacogenomics 2016; (17(9)):1005-17 doi:10.2217/pgs-2016-0004.
PMID: 27270164 - 12
Relative risk of and determinants for adverse events of methotrexate prescribed at a low dose: a systematic review and meta-analysis of randomized placebo-controlled trials.
Mazaud C, Fardet L
The British journal of dermatology 2017; (177(4)):978-986 doi:10.1111/bjd.15377.
PMID: 28182264 - 13
Effect of folate status and methylenetetrahydrofolate reductase genotypes on the complications and outcome of high dose methotrexate chemotherapy in north Indian children with acute lymphoblastic leukemia.
Moulik NR, Kumar A, Agrawal S, et al.
Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology 2016; (37(2)):85-9 doi:10.4103/0971-5851.180144.
PMID: 27168705 - 14
HLA DRB1*01 and *04 Predisposition to Rheumatoid Arthritis and Polymorphisms of the SLCO1B1, MTHFR and PNPLA3 Genes Are Not Associated with Fatty Liver and Hepatotoxicity.
Zekić T, Katalinić N, Čizmarević NS, Čubranić A
Journal of clinical medicine 2026; (15(4)) doi:10.3390/jcm15041568.
PMID: 41753255
This page is for informational purposes only and does not constitute medical advice about your MTHFR result or methotrexate treatment. Do not stop, start, or change methotrexate or folic acid without speaking with your prescriber.
Get notified when new evidence is published on Methotrexate toxicity.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.